Trial Profile

A real-world evidence (RWE), observational study of NanaBis

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 16 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nabiximols (Primary)
Indications Cancer pain; Pain
Focus Adverse reactions; Therapeutic Use
Acronyms MEDCARE

Most Recent Events

16 Jan 2023 New trial record
12 Jan 2023 According to a Medlab media release, July 2023 is approximately when the full readout of this Medcare study is expected.
12 Jan 2023 Interim results presented in a Medlab Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com